

## ESTEVE signs an agreement with AstraZeneca to market (type 2 diabetes drugs) Edistride and Ebymect in Spain

**Barcelona, 1 June 2016.-** ESTEVE has reached an agreement with AstraZeneca to market—in Spain and as of this month of June—the drugs Edistride (dapagliflozin) and Ebymect (dapagliflozin and metformin) for the treatment of type 2 diabetes in adult patients. This alliance further extends Esteve's commitment in this therapeutic area.

Edistride is an oral antidiabetic drug indicated as monotherapy in patients intolerant of metformin. Its active ingredient, dapagliflozin, reduces the absorption of glucose filtered in the kidney, thus resulting in urinary glucose excretion and further decreasing blood glucose levels in plasma.

Ebymect is another oral antidiabetic drug that combines dapagliflozin and metformin and can be used in patients not properly controlled with the maximum tolerated dose of metformin in monotherapy, or in patients already treated with the dapagliflozin/metformin combination in separate tablets.

Both medicines can be used in combination with other hypoglycemic drugs, including insulin, when these, together with diet and exercise, fail to properly control blood sugar levels.

*“Our agreement with ESTEVE clearly reflects our commitment with Spain and with national partners. We are convinced that their wide expertise in the Spanish market, their knowledge of this area and the passion for science we share will continue to improve the quality of life of diabetic patients”, states **Rodrigo Gribble**, Director of the Cardiometabolism Business Unit of AstraZeneca Spain.*

For his part, ESTEVE Farma's Managing Director **Joe Sullivan** declares that *“the alliance with AstraZeneca allows to continue offering the most innovative treatments of diabetes to both professionals and patients. It will also further strengthen our activities in this therapeutic area—a priority of the company”.*

Diabetes is a chronic disease that occurs when the pancreas fails to produce sufficient amounts of insulin or when the body cannot use the insulin it produces effectively. According to the 2015 atlas of the International Diabetes Federation, it currently affects 415 million people worldwide and is estimated to have been the direct cause of more than 5 million deaths. In Spain, the prevalence of type 2 diabetes mellitus is higher than 5 million adults, of which more than 2 million go undiagnosed, according to data from the Spanish Diabetes Association.

### **About AstraZeneca**

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammatory, autoimmune, oncologic, infectious and neurologic disorders. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: <http://www.astrazeneca.es/>

### **About ESTEVE**

ESTEVE ([www.esteve.com](http://www.esteve.com)) is a leading chemical-pharmaceutical group in Spain with a strong international presence. Founded in 1929 and presided over by Joan Esteve, the Company currently employs 2,279 people, has a presence in Europe, USA, Mexico and China, and had a sales revenue of 870 million Euros in 2015. ESTEVE is firmly committed to excellence and uses its best efforts to promote health and improve people's quality of life. Research being ESTEVE's hallmark, a portfolio of highly innovating projects ultimately aims to provide responses to unmet medical needs. Because ESTEVE is a socially responsible Company, it ensures that all projects entered by it align with its CSR vision. You may follow ESTEVE at Twitter's link: @ESTEVE\_news

### **For more information, please contact:**

M<sup>a</sup> José Egea, Atrevia, Tel. 93 419 06 30, [mjegea@atrevia.com](mailto:mjegea@atrevia.com)

Olga Cajal, ESTEVE, Tel. 93 446 62 60, [ocajal@esteve.es](mailto:ocajal@esteve.es)

Katja Soto, AstraZeneca, Tel. 91 301 90 59, [Katja.soto@astrazeneca.com](mailto:Katja.soto@astrazeneca.com)